Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) EBITDA Margin (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBITDA Margin for 5 consecutive years, with 1361.11% as the latest value for Q1 2020.

  • On a quarterly basis, EBITDA Margin rose 19072778.0% to 1361.11% in Q1 2020 year-over-year; TTM through Dec 2020 was 7214.95%, a 18355661.0% increase, with the full-year FY2019 number at 176341.67%, down 17607030.0% from a year prior.
  • EBITDA Margin was 1361.11% for Q1 2020 at Forte Biosciences, up from 117955.56% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 2368.81% in Q3 2017 to a low of 217811.11% in Q4 2018.
  • A 5-year average of 89705.14% and a median of 99700.0% in 2017 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -20830916bps in 2019, then surged 19072778bps in 2020.
  • Forte Biosciences' EBITDA Margin stood at 777.85% in 2016, then tumbled by -14072bps to 108680.0% in 2017, then tumbled by -100bps to 217811.11% in 2018, then soared by 46bps to 117955.56% in 2019, then surged by 101bps to 1361.11% in 2020.
  • Per Business Quant, the three most recent readings for FBRX's EBITDA Margin are 1361.11% (Q1 2020), 117955.56% (Q4 2019), and 208311.11% (Q3 2019).